Scott Clarke is the founder of AmbAgon Therapeutics. AmbAgon Therapeutics has raised $103M in total funding. Latest round: Series A.
Scott Clarke is the Chief Executive Officer and Director of Ambagon Therapeutics, a biotechnology company focused on unlocking intrinsically disordered proteins using molecular glue platforms. He previously served as CEO of CatalYm GmbH. Clarke is also a Director at Trishula Therapeutics and a Non-Executive Director at Novalgen Ltd.
Full founder directory · Investor directory · Company funding database · Fundraising library